10-K: Charlies Holdings Reports Steep Revenue Decline and Widening Losses Amidst Regulatory Hurdles and Going Concern Doubts

Charlies Holdings, Inc. faced a challenging 2024, reporting a significant 47.7% drop in revenue and a near doubling of its net loss, raising substantial doubt about its ability to continue as a going concern, despite strategic shifts towards non-nicotine products and ongoing regulatory compliance efforts.

Summary

• Charlies Holdings, Inc. reported a net revenue of $8.494 million for the year ended December 31, 2024, a substantial decrease of 47.7% from $16.250 million in 2023.
• The company's net loss widened significantly to $4.159 million in 2024, compared to a net loss of $2.093 million in 2023, representing a 98.7% increase in losses.
• Cash used in operating activities increased to $1.621 million in 2024 from $0.783 million in 2023, indicating a higher cash burn.
• The company's working capital position deteriorated from a surplus of $332,000 in 2023 to a deficit of $1.855 million as of December 31, 2024.
• Charlies Holdings explicitly stated that there is substantial doubt about its ability to continue as a going concern due to recurring operating losses, negative cash flows, and low working capital.
• The decline in revenue was primarily driven by a $6.481 million decrease in nicotine-based product sales and a $1.275 million decrease in hemp-derived product sales.
• The company launched its Metatine-based SBX disposable vape line in Q4 2024, which it believes is not subject to FDA review, and is test marketing it in mass market convenience chains.
• Charlies has invested over $6.5 million since 2020 in Premarket Tobacco Applications (PMTAs) and has received Acceptance Filings for more than 650 PMTA submissions as of December 31, 2024.
• In a subsequent event, the company sold 12 PACHA synthetic products and related PMTA assets to R.J. Reynolds Vapor Company for $5.0 million upfront, with a potential contingent payment of up to $4.2 million.
• The company undertook aggressive cost-cutting measures in 2024, including voluntary salary reductions for executives (20-50%) and significant headcount reductions.
• Charlies Holdings raised approximately $1.6 million in May 2024 and $550,000 in November 2024 through common stock offerings at $0.08 per share, primarily for working capital.
• Outstanding notes payable to related parties and other lenders were modified or repaid in early 2025, including a $1.25 million payment to Pinnacle Receivables Financing and a $308,000 payment to Ryan Stump.
• The company is developing patented age-gating technology for nicotine vapor products and a Metatine-based pouch line expected in late 2025.
• International sales accounted for approximately 10% of vapor product sales in 2024, and the company aims to increase this share.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to significant financial deterioration, including a near 50% revenue drop, a doubling of net losses, increased cash burn, and a substantial working capital deficit, leading to a 'going concern' warning. While strategic initiatives like the Metatine product line and PMTA monetization offer future potential, the current financial health and regulatory uncertainties present severe challenges.

Positives

• The company has strategically diversified its product portfolio by launching Metatine-based SBX disposable vapes, which it believes are not subject to current FDA tobacco regulations, offering a potential regulatory hedge and significant commercial opportunity.
• SBX Disposables have shown strong consumer preference over traditional nicotine vapes like Juul in focus group surveys, with 287 out of 306 participants preferring SBX.
• Charlies Holdings has made substantial investments of over $6.5 million in PMTA submissions, securing Acceptance Filings for more than 650 PMTAs, which management believes represent a significant standalone asset value exceeding the company's current market capitalization.
• The recent sale of 12 PACHA synthetic products and related PMTA assets to R.J. Reynolds Vapor Company for an upfront payment of $5.0 million, plus potential contingent payments of up to $4.2 million, provides a significant cash infusion and validates a portion of the company's PMTA strategy.
• The company has implemented aggressive cost structure optimization, including voluntary executive salary reductions (20-50%) and significant headcount reductions, aimed at improving margins and achieving profitability.
• Ongoing development of patented age-gating technology for nicotine vapor products demonstrates a commitment to responsible business practices and could provide a future competitive advantage in the regulated market.
• The company is actively working to upgrade its sales team and expand its international market share, which currently accounts for 10% of vapor product sales.

Negatives

• Total revenues decreased by $7.756 million, or 47.7%, from $16.250 million in 2023 to $8.494 million in 2024, indicating a severe decline in sales.
• The net loss increased by $2.066 million, or 98.7%, from $2.093 million in 2023 to $4.159 million in 2024, highlighting worsening financial performance.
• Cash used in operating activities increased from $0.783 million in 2023 to $1.621 million in 2024, reflecting an accelerated cash burn.
• The company's working capital position deteriorated significantly, moving from a surplus of $332,000 in 2023 to a deficit of $1.855 million in 2024.
• Management explicitly stated 'substantial doubt about our ability to continue as a going concern' due to recurring losses, negative cash flows, and low working capital.
• The initial launch of the SPREE BAR nicotine substitute vapor products did not meet performance expectations, necessitating further development and a new product release (SBX).
• The highly competitive and rapidly evolving vapor products industry, coupled with low barriers to entry for many products, poses ongoing challenges.
• Despite significant investment in PMTAs, the FDA has authorized very few flavored e-cigarette products, and there is no guarantee that Charlies' pending applications will receive marketing orders, which could force product removal from the market.
• The company's reliance on contractual arrangements with Don Polly, a consolidated variable interest entity owned by an entity controlled by the COO, may not provide the same level of operational control as direct ownership.
• The company has limited cash resources ($211,000 as of December 31, 2024) and may require additional financing, which is subject to market conditions and operating performance.

Risks

• The company's ability to achieve and maintain positive cash flow is uncertain, and there is no guarantee of future revenue growth or profitability.
• Limited cash resources and a working capital deficit of approximately $1.8 million as of December 31, 2024, raise substantial doubt about the company's ability to continue as a going concern, potentially leading to bankruptcy or loss of stockholder investment.
• The rapidly changing legal and regulatory environment, including new laws, regulations, or changes to existing ones, could significantly limit the company's ability to sell its products and/or result in additional costs.
• The issuance of Marketing Denial Orders (MDOs) from the FDA for nicotine-based products would increase inventory obsolescence and uncollectable accounts receivables, requiring product removal from the market.
• There is a risk that the FDA or other regulatory authorities could deem Metatine-based SBX products to be tobacco products, subjecting them to stringent regulations and potentially requiring their removal from the market.
• Products could fail to attract or retain users or generate sufficient revenue and profits, especially if new or enhanced products do not engage customers or monetization efforts are unsuccessful.
• The loss of key personnel, particularly Ryan Stump (COO) and Henry Sicignano III (President), or the failure to attract and retain other qualified personnel, could harm the business, as no succession plan is in place.
• Reliance on contractual arrangements with Don Polly, a consolidated variable interest entity, may not be as effective as direct ownership in providing operational control, and conflicts of interest with its shareholders could arise.
• The company relies on third-party contract manufacturers, and any performance failure, quality control issues, or supply chain disruptions could delay commercialization, result in product recalls, or adversely affect the business.
• The company is subject to cybersecurity risks, including data breaches, system damage, or disruptions, which could lead to operational disruptions, misappropriation of sensitive data, reputational damage, and legal claims.
• Business conducted outside the United States is subject to international risks and uncertainties, including reduced intellectual property protection, changes in tariffs, economic instability, geopolitical actions, and compliance failures.
• A future outbreak of COVID-19 or another pandemic could adversely affect the business through travel restrictions, reduced sales, and supply chain disruptions.
• Certain products contain nicotine or Metatine, which are highly addictive substances, and any new FDA regulation over these could require reformulation, recall, or discontinuation of products.
• Recent bans on flavored e-cigarettes and increasing state and local regulations directly impact the markets where Charlies products can be sold, potentially limiting sales and increasing compliance expenses.
• There is substantial concern regarding the effect of long-term use of vaping products, and conclusive determination of long-term health risks could negatively impact the business.
• The vapor products market is a niche, rapidly evolving, and uncertain market, with demand and acceptance subject to high levels of uncertainty.
• Difficulty in obtaining desired insurances (general liability, D&O) due to operations in highly regulated industries may expose the company to additional risk and financial liability.
• Intense competition from numerous resellers, manufacturers, and wholesalers, including 'Big Tobacco' companies with vast resources, could lead to price competition and diminished economic viability.
• Adverse publicity associated with the company's products or ingredients, or those of similar companies, could negatively affect sales and revenue.
• Products may not meet health and safety standards or could become contaminated, leading to production interruptions, recalls, and liability claims.
• Limited availability of clinical studies related to many products, and potential for illness or negative side effects from product use, could materially adversely affect the business.
• The sale of products involves product liability and related risks, which could expose the company to significant insurance and loss expense.
• The success of the business depends on the ability to create and expand brand awareness amidst advertising and packaging limitations due to regulations.
• The company must continuously develop and introduce new products to remain competitive, and success is dependent on factors like proper product selection, sales efforts, timely delivery, raw material availability, and regulatory allowance.
• Inability to adequately protect intellectual property (product formulations, trademarks) could hinder competition and profitability.
• A limited trading market for common stock on OTCQB and potential sales of substantial numbers of shares could adversely impact the stock price and result in further dilution to existing stockholders.
• Holders of Series A Convertible Preferred Stock have substantial rights senior to common stock, including liquidation preference and anti-dilution provisions, which could cause dilution or limit cash.
• The price of the company's securities could be subject to wide fluctuations due to operating results, working capital, going concern issues, FDA actions, and market expectations.
• The company's common stock may be classified as penny stock, limiting trading and potentially causing price decline.
• The company has issued Preferred Stock with senior rights and may issue additional Preferred Stock without stockholder approval, which could have dividend, voting, liquidation, and other rights senior to common stock.
• The company's Amended and Restated Bylaws designate Nevada courts as the sole and exclusive forum for certain actions, which could limit stockholders' ability to obtain a favorable judicial forum.
• Stockholders should not rely on an investment in common stock for cash dividends, as the company has never paid them and does not anticipate doing so in the foreseeable future.

Future Outlook

Charlies Holdings plans to dramatically expand its business into nicotine substitute products, particularly with its Metatine-based SBX line, which it believes is not subject to FDA review, aiming to capture significant future sales and market share. The company intends to monetize its substantial PMTA portfolio, which includes over 650 Acceptance Filings, by seeking strategic partners. It is also developing patented age-gating technology to prevent youth access to vapor products, viewing it as both a responsible practice and a competitive advantage. Furthermore, Charlies aims to grow its international market share beyond the current 10% and plans to uplist from the OTCQB exchange to a national securities exchange once it meets listing requirements, expecting increased market visibility, liquidity, and access to capital.

Management Comments

• "Charlies has focused on achieving full compliance with FDA regulations – while also establishing a regulatory hedge through the development of alternative zero-nicotine product lines that are not currently subject to FDA review."
• "The Company believes that its nicotine substitute, Metatine, in the SBX product line, will position the Company to capture very significant future sales and market share in the vapor products marketplace."
• "The Company believes Charlies 650+ PMTAs, as a stand-alone asset, have a monetary value that far exceeds Charlies current market cap."
• "By investing an additional $1.2 million in Q4 2024 to amend and enhance certain of our 2022 PMTA submissions, we maintained our commitment to full regulatory compliance, and we enhanced the strategic value of our PMTA portfolio."
• "We believe this [age-gating technology] is both a responsible business practice as well as a potential future competitive advantage in the marketplace."
• "In order to right-size the Company during a time of significantly reduced revenue, we continue to reduce our overall cost structure while improving margins. Company executives voluntarily reduced their salaries by 20-50%."
• "If one or more of these tests [SBX in mass market convenience chains] prove successful, regional and national rollouts could prove transformational for Charlies."
• "Given that Charlies 650+ PMTAs (primarily for flavored vapor products) remain among the fraction of 1% that are still under active review with the FDA, and given that more than 80% of adults in the United States prefer flavored vapor products over plain tobacco vapor products, we believe that Charlies PMTA portfolio represents an important competitive advantage – of significant monetary value."
• "If our age-gated e-cigarettes-in-development are recognized as 'products of merit' by the FDA, Charlie's e-cigarettes could emerge among the select minority of flavored nicotine disposables able to be sold legally in the $8 billion U.S. vapor products market."

Industry Context

The company operates in a highly competitive, fragmented, and rapidly evolving vapor products industry. This industry faces significant governmental and private sector actions, including increasing FDA regulation, state and local flavor bans, and efforts to reduce underage use. The FDA's authority over nicotine products, including synthetic nicotine, has expanded, requiring costly PMTA submissions with very few marketing orders granted for flavored products. The emergence of alternative alkaloids like Metatine represents a strategic response to these regulatory pressures, as these products are currently not subject to the same FDA restrictions as nicotine-derived products. The market is dominated by 'Big Tobacco' companies with vast resources and established distribution, posing a significant competitive challenge for smaller players like Charlies Holdings.

Comparison to Industry Standards

• Charlies' SBX Disposables, containing Metatine, are positioned as a zero-nicotine alternative that is not subject to FDA tobacco product regulations or state flavor bans, unlike many traditional nicotine vapes.
• In a company-sponsored focus group, Charlies' SBX Disposables were overwhelmingly preferred over Juul tobacco-flavored vapes (287 out of 306 participants), suggesting a strong competitive edge in consumer preference for flavored alternatives.
• Despite the FDA receiving nearly 27 million ENDS product applications, it has authorized fewer than three dozen tobaccoand menthol-flavored e-cigarette products and devices, highlighting the extreme difficulty in obtaining marketing orders for nicotine products. Charlies' 650+ PMTA Acceptance Filings, particularly for flavored products, are noted as being among the very small fraction still under active review, positioning them uniquely within the industry's regulatory landscape.
• The company's development of age-gating technology aligns with initiatives by major industry players like JUUL Labs, Altria, and R.J. Reynolds, indicating a shared industry focus on addressing underage access concerns, which could be a key differentiator for future FDA approvals.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the filing, the Company is not a party to any material legal or administrative proceedings.

Related Party Transactions

• Don Polly, LLC, a consolidated variable interest entity, is owned by an entity controlled by Ryan Stump, the Company's Chief Operating Officer. Charlies provides Don Polly with intellectual property licenses and services, receiving 75% of net profits from licensing and 25% from services. Charlies also has an exclusive right of first refusal to purchase Don Polly for $111,618 on or before December 31, 2025.
• The Company leases its corporate headquarters in Costa Mesa, California, from Brandon Stump (former CEO), Ryan Stump (COO), and Keith Stump (former Board member). The total amount paid for this lease to related parties was $275,280 for both 2024 and 2023.
• The Company leases its satellite sales office in Williamsville, New York, from Henry Sicignano Jr., a relative of the Company's President, Henry Sicignano III. The lease has a base rent of $1,650 per month.
• The Company had outstanding promissory notes with related parties, including Ryan Stump and Henry Sicignano III (July 2023 Note Financing, $400,000 outstanding as of Dec 31, 2024, modified April 28, 2025), Michael King (April 2022 Note Financing, $793,000 outstanding as of Dec 31, 2024, modified April 28, 2025), and Ryan Stump (August 2022 Note Financing, fully repaid April 28, 2025).

Stakeholder Impact

• Shareholders face significant dilution risk from potential future common stock issuances and conversions of preferred stock and options, as well as the risk of losing their investment due to the company's going concern doubts.
• Employees have experienced headcount reductions and voluntary salary cuts for executives, indicating pressure on compensation and job security.
• Customers may face uncertainty regarding product availability due to evolving and inconsistent regulatory environments, particularly for nicotine-based products.
• Creditors face increased risk due to the company's negative working capital and substantial doubt about its ability to continue as a going concern, although recent debt modifications and repayments indicate efforts to manage obligations.
• Suppliers may experience fluctuations in demand and payment terms given the company's financial challenges and reliance on third-party manufacturers.

Next Steps

• Continue to develop and expand the Metatine-based SBX product line and other alternative alkaloid products, including a Metatine-based pouch line expected in late 2025.
• Seek strategic partners to monetize the company's portfolio of over 650 PMTA Acceptance Filings.
• Continue to seek FDA marketing authorization for certain nicotine vapor products and synthetic nicotine vapor products.
• Continue development of patented age-gating technology for nicotine vapor products and seek strategic partnerships for its implementation.
• Develop new distribution partnerships to grow the nicotine disposable business in 2025.
• Increase market share internationally, building on the existing international distribution platform.
• Uplist from the OTCQB exchange to a national securities exchange as soon as listing requirements can be met.

Key Dates

Recommendation

Keywords

Vaping, E-cigarettes, Nicotine, Metatine, SBX, FDA Regulation, PMTA, Vapor Products, Financial Performance, Annual Report, 10-K, Charlies Holdings, Going Concern, Disposable Vapes, Alternative Alkaloids, Pacha, Pachamama